Abbott’s Tendyne valve shows early promise in calcification
Feasibility trial success could mean a new therapy, but not for a few years yet.
World Lung 2019 – Oncimmune’s liquid biopsy hits in large trial
The data are positive, but might not do much for the company’s sales.
Stryker spends $500m to re-up on robots
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
ESC 2019 – Carmat is stout-hearted in the face of a challenging schedule
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
ESC 2019 – Trial failure leaves Cellaegis in limbo
Before today’s trial readout no one was sure how remote ischaemic conditioning worked; now the investigators are pretty certain that it doesn’t.
The extremes converge in big medtech’s hiring practices
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
Digital therapeutics have potential but commercial success unproven
Software can be a medical device. Can it also be a drug?
Atricure lassoes Sentreheart for $40m
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.